Abstract:The aim of the present study was to investigate the relative bioavailability and bioequivalence of a new tablet formulation of metformin hydrochloride with reference to a standard product in healthy Chinese adult male volunteers. Two randomized, comparative, two-way crossover studies were therefore conducted. In study 1, which was a single-dose study, 20 subjects received 1000 mg metformin hydrochloride lest product extended-release (MXR) tablets followed by the same amount of metformin hydrochloride reference product immediate-release (MIR) tablets with a 7-day washout period between the two doses. In study 2, which was a multiple-dose study, 22 subjects received MXR 1000 mg/d for 9 consecutive days followed by MIR 1000 mg/d with a 14-day washout period between the doses of the test and reference product. The serum metformin concentrations were monitored using a selective and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection. The pharmacokinetic parameters were calculated using a 3P97 program. Analysis of variance (ANOVA) of the half-life of the absorption phase (t1/2ka), the half-life of the elimination phase (t1/2kc) and the mean retention time (MRT) and the Wilcoxon Signed Rank test of Tmax for the two preparations were significantly different. A significant difference was found in the ANOVA for Cmax in the single-dose study, while this was not the case in the multiple-dose study. Two one-sided t-tests showed that there were no significant differences in the area under the concentration-time curve (AUC) values between the two formulations. The present study indicates that the test preparation was bioequivalent to the reference preparation when both MXR and MIR were investigated in healthy Chinese adult male volunteers. And on the basis of the mean AUC0−t, AUC0−∞ and AUCss, the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.

Relative Bioavailablity of Micronised Fenofibrate Dispersion Table in Human Volunteers

Absolute Oral Bioavailability of Fenofibric Acid and Choline Fenofibrate in Rats Determined by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry

Bioequivalence of Micronized Fenofibrate Capsule in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Preparation and Bioavailability Evaluation of Fenofibrate Nanosuspension

Enhanced Bioavailability of the Poorly Water-Soluble Drug Fenofibrate by Using Liposomes Containing a Bile Salt

Relative Bioavailablity of Cefaclor Effervescent Tabletsin Human Volunteers

The relative bioavailability of two kinds of fluconazole dispersible tablets and fluconazole capsules in healthy volunteers

Pharmacokinetics and Relative Bioavailablity of Domestic Penicillin V Dispersion Tablet

Bioeguivalent Study of Two Fluconazole Capsules in Human Plasma

Relative Bioavailability of Ibuprofen Sustained-release Capsules in Human Subjects

Bioequivalence of terbinafine hydrochloride tablets in healthy volunteers

Bioequivalence of Diclofenac Sodium Sustained Release Tablets in Human Plasma

The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule

Relative bioavailability of mycophenolate mofetil capsules in healthy volunteers

Pharmacokinetics and Relative Bioavailablity of Gatifloxacin Capsule in Human Volunteers

Relative Bioavailability and Bioequivalence of Metforphin Hydrochloride Extended-Released and Immediate-Released Tablets in Healthy Chinese Volunteers

A Study of the Bioequivalence of Fleroxacin Tablets in Healthy Chinese Volunteers

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Pharmacokinetics and Bioequivalance of Ibuprofen Tablet in Healthy Volunteers

Study of the Bioequivalence of Isopropiram Fumarate Tablets in Healthy Volunteers